November 22, 2019
  • November 22, 2019
Breaking News

Health

Strike by 4,000 Medical Professionals Postponed following the Kaiser Permanente CEO’s Death

by on November 11, 2019 0

Almost more than 4,000 psychologists, and other medical professionals, who were set to strike, had postponed their strike against the health care provider Kaiser Permanente indefinitely following the death of CEO Bernard Tyson on Sunday.   From Monday to Friday, the National Union of Healthcare Workers was set to strike, to demand Kaiser Permanente...

Read More

A Person Died in California, 9 More Sickened in Multistate Linked to Ground Beef Salmonella Outbreak

by on November 5, 2019 0

A person died in California and nine others were sickened, in a six-state salmonella outbreak that is linked to ground beef, according to Centers for Disease Control and Prevention.   10 people were found infected with salmonella Dublin that also includes two people in California, two in Kansas, three in Colorado, and one each...

Read More

Immunomedics, Inc. (NASDAQ:IMMU) executive board chair indirectly purchase million more shares

by on July 3, 2019 0

Immunomedics, Inc. (NASDAQ:IMMU) saw its executive board chair, Behzad Aghazadeh, step up again and indirectly purchase a million more shares of this biopharmaceutical company. At prices ranging from $13.21 to $13.84 per share, that cost him almost $13.55 million. The insider ownership percentage is the key indicator, can be used by investors, to measure...

Read More

Don’t Miss: Xenetic Biosciences, Inc. (NASDAQ:XBIO)

by on July 3, 2019 0

Xenetic Biosciences, Inc. (NASDAQ:XBIO) filed prospectus for offering of 1.6 million shares of common stock & warrants. The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the XBIO is 58.20%. Institutional ownership refers to the ownership...

Read More

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results that could bode well for migraine patients

by on July 3, 2019 0

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results Tuesday that could bode well for migraine patients. At the Fifth Congress of the European Academy of Neurology held in Oslo, Norway, Teva presented additional positive results from a Phase 3b exploratory study dubbed FOCUS that evaluated its migraine drug fremanezumab in adults who previously experienced...

Read More

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study

by on July 2, 2019 0

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. The data from the trial are supportive of the primary study...

Read More